相似文献
1
Organizing Pneumonia Associated with Pegylated Interferon α and Ribavirin Therapy.
Case Rep Pulmonol. 2015;2015:794592. doi: 10.1155/2015/794592. Epub 2015 Jan 29.
2
[Antiviral/immunomodulatory combination therapy: pegylated interferon alpha 2a and ribavirin in patients with chronic hepatitis C virus infection].
Srp Arh Celok Lek. 2012 Sep-Oct;140(9-10):612-8. doi: 10.2298/sarh1210612d.
3
Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. doi: 10.3310/hta8390.
4
Response to pegylated interferon alpha-2b and ribavirin in children with chronic hepatitis C.
J Clin Gastroenterol. 2007 Jan;41(1):111-4. doi: 10.1097/MCG.0b013e31802dd2f6.
5
Interstitial pneumonitis after combination therapy with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C.
Chang Gung Med J. 2007 Jan-Feb;30(1):92-7.
6
Cost Effectiveness of Daclatasvir Plus Asunaprevir Therapy for Chinese Patients with Chronic Hepatitis C Virus Genotype 1b.
Clin Drug Investig. 2018 May;38(5):427-437. doi: 10.1007/s40261-018-0621-9.
7
Erythema annulare centrifugum due to pegylated interferon-α-2a plus ribavirin combination therapy in a patient with chronic hepatitis C virus infection.
J Cutan Med Surg. 2014 Jan-Feb;18(1):65-8. doi: 10.2310/7750.2013.13051.
8
Severe liver injury associated with simeprevir plus pegylated interferon/ribavirin therapy in a patient with treatment-naïve genotype 1b hepatitis C virus: a case report.
Clin J Gastroenterol. 2014 Oct;7(5):465-70. doi: 10.1007/s12328-014-0527-x. Epub 2014 Aug 27.
9
Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.
Ann Intern Med. 2013 Dec 3;159(11):729-38. doi: 10.7326/0003-4819-159-11-201312030-00005.
10
Severe Interferon/Ribavirin-Induced Hyperuricemia and Urate Nephropathy Requiring Rasburicase and Hemodialysis in a Liver Transplant Recipient.
Exp Clin Transplant. 2015 Dec;13(6):596-9. doi: 10.6002/ect.2014.0081. Epub 2015 Mar 24.
本文引用的文献
1
Secondary bronchiolitis obliterans organizing pneumonia during treatment of chronic hepatitis C: role of pegylated interferon alfa-2a.
Rev Soc Bras Med Trop. 2012 Oct;45(5):655-6. doi: 10.1590/s0037-86822012000500023.
2
Diagnosis, management, and treatment of hepatitis C: an update.
Hepatology. 2009 Apr;49(4):1335-74. doi: 10.1002/hep.22759.
3
[Organizing pneumonia associated with the use of pegylated interferon alfa].
Arch Bronconeumol. 2008 Mar;44(3):173-4.
4
Onset of bronchiolitis obliterans organizing pneumonia in a liver transplant recipient under peg-interferon and ribavirin treatment.
Intern Emerg Med. 2008 Mar;3(1):77-80. doi: 10.1007/s11739-008-0098-2. Epub 2008 Feb 7.
5
Interstitial pneumonitis after combination therapy with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C.
Chang Gung Med J. 2007 Jan-Feb;30(1):92-7.
6
Spectrum of pulmonary toxicity associated with the use of interferon therapy for hepatitis C: case report and review of the literature.
Clin Infect Dis. 2004 Dec 1;39(11):1724-9. doi: 10.1086/425746. Epub 2004 Nov 8.
7
Side effects of therapy of hepatitis C and their management.
Hepatology. 2002 Nov;36(5 Suppl 1):S237-44. doi: 10.1053/jhep.2002.36810.
8
The burden of hepatitis C in the United States.
Hepatology. 2002 Nov;36(5 Suppl 1):S30-4. doi: 10.1053/jhep.2002.36791.
9
Structure, biology, and therapeutic implications of pegylated interferon alpha-2b.
Curr Pharm Des. 2002;8(24):2139-57. doi: 10.2174/1381612023393242.
10
Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C.
Am J Gastroenterol. 2002 Sep;97(9):2432-40. doi: 10.1111/j.1572-0241.2002.05999.x.
Zotero 插件
